Skip to main content
SpringerLink
Log in

A Phase II Trial of Pyrazoloacridine (PZA) in Squamous Carcinoma of the Cervix – A Gynecologic Oncology Group Study

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Purpose: The Gynecologic Oncology Groupperformed a Phase II study to determine the response rate ofPyrazoloacridine (PZA) in patients with advanced, persistentor recurrent squamous carcinoma of the cervix.Methods: PZA was administered at a dose of 750mg/m2 intravenously over three hours every threeweeks. Results: Among 21 evaluable patients, therewere no complete and one (4.2%) partial response. Themajor toxicities were hematologic. Conclusion: PZA atthe dose and schedule employed has insignificant activity inthis population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Perez CA, Camel MH, Kuske RR, Kao MS, Galakatos A, Hederman MA, Powers WE: Radiation alone in treatment of carcinoma of the uterine cervix: A 20 year experience. Gynecol Oncol 23: 127–40, 1986

    Google Scholar 

  2. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J: Cisplatinum in the treatment of advanced or recurrent squamous carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group. Cancer 48(4): 899–903, 1981

    Google Scholar 

  3. Sutton GP, Blessing JA, Adcock L, Webster KD, DeEulis T: Phase II study of Ifosfamide and mesna in patients with previously treated carcinoma of the cervix: A Gynecologic Oncology Group study. Invest New Drugs 7: 341–343, 1989

    Google Scholar 

  4. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G: Paclitaxel has moderate activity in squamous cervix cancer: A Gynecologic Oncology Group study. J Clin Oncol 14: 792–795, 1996

    Google Scholar 

  5. Stehman FB, Blessing JA, McGehee R, Barrett RJ: A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. J Clin Oncol 7: 1892–1895, 1989

    Google Scholar 

  6. Omura G, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch D, Anderson Barrie. Randomized trial of cisplatin versus cisplatin plus mitolactol (dibromodulcitol) versus cisplatin plus ifosfamide in advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 15: 165–171, 1997

    Google Scholar 

  7. Annual report to the Food and Drug Administration, Pyrazoloacridine NSC #366140, IND #36325, 1993

  8. LoRusso, P, Foster, BJ, Poplin E, McCormick J, Kraut M, Flaherty Heilbrun LK, Valdivieso M, Baker L: Phase I clinical trial of pyrazoloacridine (PD115934). Clin Cancer Res 1: 1487–1493, 1995

    Google Scholar 

  9. Zalupski MM, Shields AF, Philip PA, Kraut M, LoRusso P, Heilbrun LK, Vaitkevicius V: Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Invest New Drugs 16: 93–96, 1998

    Google Scholar 

  10. Zalupski MM, Philip PA, LoRusso P, Shields AF: Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemother Pharmacol 40: 225–227, 1997 Address for offprints: Steven Plaxe, M.D., UCSD Medical Center, Department of Reproductive Medicine, 402 Dickinson Street, San Diego, CA, 92103–8433, Tel.: 619–543–6905, Fax: 619–543–3703.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gynecologic Oncology, University of California, San Diego, San Diego, CA, USA

    Steven C. Plaxe (Associate Professor and Director)

  2. Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, NY, USA

    John A. Blessing (Director of Statistics)

  3. Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Joseph A. Lucci (Assistant Professor)

  4. Section of Gynecologic Oncology, Indiana University Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA

    Jean A. Hurteau (Assistant Professor)

Authors
  1. Steven C. Plaxe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John A. Blessing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph A. Lucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean A. Hurteau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plaxe, S.C., Blessing, J.A., Lucci, J.A. et al. A Phase II Trial of Pyrazoloacridine (PZA) in Squamous Carcinoma of the Cervix – A Gynecologic Oncology Group Study. Invest New Drugs 19, 77–80 (2001). https://doi.org/10.1023/A:1006469006460

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006469006460

Search

Navigation